Tempol-nebivolol therapy potentiates hypotensive effect increasing NO bioavailability and signaling pathway

摘要

Nebivolol is a third generation beta blocker with endothelial nitric oxide synthase (eNOS) agonist properties. Considering the role of reactive oxygen species (ROS) in the uncoupling of eNOS, we hypothesized that the preadministration of an antioxidant as tempol, could improve the hypotensive response of nebivolol in normotensive animals increasing the nitric oxide (NO) bioavailability by a reduction of superoxide (O-2(center dot-)) basal level production in the vascular tissue.